Janet Soul is an Associate Professor of Neurology at Harvard Medical School and the Director of the Fetal-Neonatal Neurology Program at Boston Children’s Hospital. Dr. Soul obtained her medical degree at McGill University in Montreal, Canada, then moved to Boston to complete her pediatric residency, Child Neurology training in the Harvard Longwood Neurology Program, and a Neonatal Neurology Fellowship under the mentorship of Dr. Joseph Volpe.  Dr. Soul provides care to fetuses, newborns and children whose neurologic disorders begin in utero or during the newborn period.  The multidisciplinary clinical program she directs also provides specialized training for neurology, neonatology and pediatric fellows, residents and medical students.

Dr. Soul’s clinical research is focused on improving the management and outcome of neonatal seizures and brain injury, particularly hypoxic-ischemic brain injury.  She was the Principal Investigator of a randomized, double-blind, controlled trial of bumetanide to treat neonatal seizures (NCT00830531), the first neonatal seizure trial to employ a standard therapy control group with an add-on therapy design to test a novel drug whose anticonvulsant mechanism was specific to the newborn brain. She co-chaired the Seizure Workgroup of the International Neonatal Consortium (Critical Path Institute) to develop consensus recommendations for the design of neonatal seizure treatment trials.   She has been funded by the NIH, March of Dimes, Hood Foundation, United Cerebral Palsy Foundation, and others, and has served on DSMBs for NIH-funded multicenter trials in Neonatal Neurology.